首页> 外国专利> MARKER FOR DIAGNOSING PROSTATE CANCER SUSCEPTIBILITY CONTAINING POLYMORPHIC SITE OF RETN GENE AND A METHOD FOR PREDICTING AND DETERMINING PROSTATE CANCER SUSCEPTIBILITY USING THE SAME

MARKER FOR DIAGNOSING PROSTATE CANCER SUSCEPTIBILITY CONTAINING POLYMORPHIC SITE OF RETN GENE AND A METHOD FOR PREDICTING AND DETERMINING PROSTATE CANCER SUSCEPTIBILITY USING THE SAME

机译:诊断包含retn基因多态性的前列腺癌敏感性的标志物以及使用相同方法预测和确定前列腺癌敏感性的方法

摘要

PURPOSE: A marker for diagnosing prostate cancer susceptibility using RETN(resistin) gene is provided to diagnose risk of prostate cancer and predict susceptibility to prostate cancer.;CONSTITUTION: A marker for diagnosing prostate cancer susceptibility contains polymorphic site of RETN gene. The polymorphic site of the RETN gene has 201th base of sequence number 1 in which C is substituted with G. A kit for diagnosing prostate cancer contains a primer for amplifying a polynucleotide containing 201th base of sequence number 1. The primer has sequences of sequence number 6 and 7. A method for predicting and determining prostate cancer susceptibility comprises: a step of collecting nucleic acid sample from a sample; a step of amplifying 201th base polymorphic site of sequence number 1 in the nucleic acid sample; and a step of determining amplified polymorphic site and analyzing risk of prostate cancer.;COPYRIGHT KIPO 2010
机译:目的:提供一种利用RETN(resistin)基因诊断前列腺癌易感性的标志物,以诊断前列腺癌的风险并预测对前列腺癌的易感性。;构成:诊断前列腺癌易感性的标志物包含RETN基因的多态性位点。 RETN基因的多态性位点具有序列号1的第201个碱基,其中C被G取代。用于诊断前列腺癌的试剂盒包含用于扩增含有序列号1的第201个碱基的多核苷酸的引物。参见图6和7。一种预测和确定前列腺癌易感性的方法包括:从样品中收集核酸样品的步骤;以及从样品中收集核酸样品的步骤。扩增核酸样品中序列号1的第201个碱基多态性位点的步骤;以及确定扩增的多态性位点和分析前列腺癌风险的步骤。; COPYRIGHT KIPO 2010

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号